DDInter1387 DDInter1435
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Panobinostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen